BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Waters Launches HPLC/UPLC-MALS Integration Software for Advanced Biologic Drug Characterization

At Pittcon 2024, Waters Corporation (NYSE:WAT) unveiled the HPLC CONNECT software, a comprehensive software solution designed to facilitate seamless digita...

February 29, 2024 | News

Teva Partners with Jiangsu Nhwa to Enhance AUSTEDO® Access in China

“Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee,...

February 28, 2024 | News

BioCina and NovaCina Join Forces for Integrated Biologics Solutions

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish...

February 28, 2024 | News

Neomorph, Novo Nordisk Partner on Molecular Glue Degraders for Diseases

Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases ...

March 27, 2024 | News

Charles River and Wheeler Bio Forge Strategic Alliance to Streamline Drug Development Process

This partnership aims to enhance therapeutic discovery and expedite the journey to Investigational New Drug (IND) submission by combining Charles R...

February 23, 2024 | News

Ono Pharmaceutical Partners with InveniAI to Revolutionize Drug Discovery Using AI

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") has announced a strategic partnership with the AI-driven company InveniAI...

February 22, 2024 | News

Hox Therapeutics and Vernalis Enter Collaboration to Advance Oncology Drug Discovery

Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...

February 22, 2024 | News

Japan Becomes First in the World to Approve Dupixent® for Chronic Spontaneous Urticaria (CSU)

Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth appr...

February 17, 2024 | News

FDA Prioritizes Review of Bristol Myers Squibb's Augtyro™ for NTRK-Positive Solid Tumors

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for A...

February 15, 2024 | News

GSK Secures License for Elsie Biotechnologies' Cutting-Edge Discovery Platform

Kevin Green, Chief Operating Officer of Elsie Biotechnologies, expressed enthusiasm, stating, "We are pleased that GSK ha...

February 15, 2024 | News

Atara Biotherapeutics Submits Investigational New Drug Application for ATA3219 to Treat Lupus Nephritis

Lupus nephritis, a condition affecting the kidneys, presents a challenging treatment landscape with limited efficacy from existing therapies. ATA32...

February 15, 2024 | News

BioAge Secures $170 Million in Series D Funding to Propel Obesity and Metabolic Disease Drug Development

BioAge Labs (“BioAge”), a pioneering biotechnology firm dedicated to advancing novel treatments for obesity and metabolic diseases by e...

February 14, 2024 | News

VantAI and Bristol Myers Squibb Forge AI-Driven Partnership to Propel Molecular Glue Drug Discovery

VantAI, a trailblazer in artificial intelligence (AI)-enabled drug discovery, has announced a groundbreaking collaboration with pharmaceutical giant Bristo...

February 14, 2024 | News

Innovent Biologics Advances Novel Weight Management Drug Mazdutide with NDA Acceptance in China

This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...

February 08, 2024 | Regulatory

Stay Connected